Overview
BiOkuris develops next-generation medical nutrition products tailored to unmet medical needs of patients with chronic intestinal diseases such as IBS, IBD, and Candidiasis. The company's solutions are designed to improve physiopathology and quality of life for patients with these conditions. The company announced positive results from a pivotal IBS study evaluating BK002.
In the news
- It’s time to get back to business! 💼 After the summer break, the whole team is now ready to kick off the second half of the year, with an exciting range of projects, meetings and opportunities ahead. BiOkuris will be attending the following business development meetings this autumn, connecting with potential partners and exploring new licensing and collaboration opportunities: 🔹 #PharmaSynergy Rome, 10-11 September 🔹 CPHI Milan, 6-7 October 🔹 #EuroPLX 92 Rome, 16-17 November We’ll also be taking part in two key industry events,
- De Waalse kampioenen ». C’est la série d’articles que le journal De Standaard entame avec KitOzyme comme premier « champion ». Une très belle occasion de faire ainsi mieux connaître la biotech « Made in Wallonië » dans notre propre pays. … Une belle ouverture d’esprit ! Et l’occasion de se réjouir de l’initiative. Bravo ! De Standaard Giselle Nath (PhD) bio.be KitOzyme KiOmed Pharma BiOkuris
- Living with digestive discomfort is more than just a physical burden, it can significantly affect quality of life. Discomfort, unpredictability, and emotional strain make everyday routines difficult for many individuals. Yet most solutions focus on individual symptoms rather than the broader impact on well-being. BK005 was developed with this broader patient experience in mind, providing digestive support while improving overall well-being. 🔬Proprietary solution combining: - Chitin-glucan (Biokuris proprietary
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.